Pfizer: FDA nods PAXVOLID
(CercleFinance.com) - Pfizer announced yesterday that the US FDA Antimicrobial Drug Advisory Committee (AMDAC) has voted 16-1 that data supports the safety and efficacy of PAXLOVID for the treatment of COVID-19 in adult patients at high risk of progression to severe disease.
The AMDAC vote, while non-binding, will be taken into account by the FDA when making its decision regarding the potential approval of PAXLOVID.
The company believes that it is critical that adults at high risk of progressing to severe COVID-19 have access to safe and effective treatment options, such as PAXLOVID, to avoid preventable hospitalizations and deaths, Pfizer said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The AMDAC vote, while non-binding, will be taken into account by the FDA when making its decision regarding the potential approval of PAXLOVID.
The company believes that it is critical that adults at high risk of progressing to severe COVID-19 have access to safe and effective treatment options, such as PAXLOVID, to avoid preventable hospitalizations and deaths, Pfizer said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.